SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-19-012157
Filing Date
2019-06-17
Accepted
2019-06-17 10:00:37
Documents
12
Period of Report
2019-06-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20190614_8k.htm 8-K 34017
2 EXHIBIT 1.1 ex_147590.htm EX-1.1 270995
3 EXHIBIT 4.1 ex_147673.htm EX-4.1 114506
4 EXHIBIT 5.1 ex_147591.htm EX-5.1 11145
5 EXHIBIT 99.1 ex_147592.htm EX-99.1 14519
6 EXHIBIT 99.2 ex_147593.htm EX-99.2 13622
7 EXHIBIT 99.3 ex_147594.htm EX-99.3 12582
8 eximg01.jpg GRAPHIC 13674
9 eximg02.jpg GRAPHIC 14591
10 eximg03.jpg GRAPHIC 7013
11 eximg04.jpg GRAPHIC 3434
12 eximg05.jpg GRAPHIC 6156
  Complete submission text file 0001437749-19-012157.txt   535045
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 19900630
SIC: 2835 In Vitro & In Vivo Diagnostic Substances